SAN MARCOS, Calif., April 15, 2016 — Natural Alternatives International, Inc. (“NAI”) (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. RE45,947 entitled “Methods and compositions for increasing the anaerobic working capacity in tissues.” The newly reissued patent becomes part of NAI’s global patent estate covering its CarnoSyn® beta-alanine product.
Mark A. LeDoux, NAI’s CEO and Chairman of the Board, said that “this new patent is yet another example of NAI’s ongoing commitment to the growth and protection of its CarnoSyn® beta-alanine patent portfolio. We will continue to pursue opportunities to expand our CarnoSyn® business around the world through vigorous research, development and enforcement of intellectual property.” NAI’s new patent contains claims directed to beta-alanine compositions, wherein the beta-alanine is not part of a dipeptide, polypeptide or oligopeptide and is in the form of a dietary supplement, with additional active agents, such as carbohydrates and creatine.
NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI’s clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at http://www.nai-online.com.
This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or inv[email protected].
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/natural-alternatives-international-inc-announces-issuance-of-new-us-beta-alanine-patent-300252323.html?
SOURCE Natural Alternatives International, Inc.